Despite this transfer, when isolated from tumor-draining lymph nodes and tested ex vivo, only migratory CD103+ cDC1s, but not lymph node–resident CD8α+ cDC1s, have the capacity to stimulate naive CD8+ T cells against tumor-associated model antigens 11, 38. The gene discussed is CD8A; the disease is neoplasm.